Cooling adjunct for medications to treat disorders in the nasal cavity
View Patent ↗The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-alkyl-phosphinoyl-alkanes as described herein, DIPA-1-8 and DIPA-1-9, and 2-6 and 2-7 that are collectively referred to herein as “DAPA compounds”, that are useful in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by inflammation, irritation, itch, or pain) in the nasal cavity. The applicant has found that localized delivery of DAPA compounds in combination with an intranasal steroid or an intranasal antihistamine immediately relieves nasal discomfort and enhances patient adherence to the use of the nasal medications.
1. A method for relieving sensory discomfort caused by allergic or perennial allergic rhinitis in a subject, comprising:
intranasally administering to the subject in need thereof a therapeutically effective amount of a composition in a liquid solution comprising 1-[Diisopropyl-phosphinoyl]-nonane and azelastine hydrochloride, the amount of 1-[Diisopropyl-phosphinoyl]-nonane being at a concentration of 1 to 10 mg/ml, the amount of composition administered being therapeutically effective to reduce nasal congestion.
2. The method as in claim 1 wherein the composition is in the form of an aerosol, nasal drops, a nasal spray or an irrigation solution.
3. The method as in claim 1 wherein azelastine hydrochloride administered is in an amount of about 0.1 to 5 mg/mL.
4. The method as in claim 1 wherein the liquid solution is an isotonic or hypertonic saline solution.
5. The method as in claim 1 wherein the administering leads to an increased compliance or adherence to use of the composition by the subject.
6. A method of increasing compliance or adherence to treatment in a patient in need of an intranasal medication for the treatment of sensory discomfort in a nasal cavity caused by allergic or perennial allergic rhinitis, comprising:
providing an aqueous liquid composition having a therapeutic amount of 1-[Diisopropyl-phosphinoyl]-nonane therein and azelastine hydrochloride, wherein the therapeutic amount of 1-[Diisopropyl-phosphinoyl]-nonane is a concentration of 1 to 10 mg/mL in the liquid composition, the aqueous liquid composition being a hypertonic saline solution, or an isotonic saline solution;
instructing a user in intranasally administering said composition; and
administering the composition to said patient.
7. The method as in claim 6 wherein the instructing provides for the administering of from about 0.1 to 5 mg/mL of azelastine hydrochloride.
8. The method as in claim 6 wherein the therapeutic amount of 1-[Diisopropyl-phosphinoyl]-nonane is therapeutically effective to reduce nasal congestion in less than about two minutes.